We always have something going on at Juno.
Want to keep up with our most recent developments?
Have a read of our latest news, new product launches and business news.
Filter News by:

Juno Pharmaceuticals $30,000 Emerging Researcher Grant

Juno’s support of the Society of Hospital Pharmacists of Australia (SHPA) has today been strengthened, with the announcement of a new $30,000 research grant. The provision of this grant will provide up and coming Australian clinical pharmacists with an unprecedented opportunity to improve patient safety in the use of high-risk medicines. Read more

Amneal Portfolio Acquisition

Juno Pharmaceuticals today announced it has acquired the Amneal injectables, ophthalmic, and oncology portfolio. This business primarily has a focus on Australian hospital customers. Read more

Juno Pharmaceuticals appointed by Celgene Pty as Strategic Partner for its maturing brand Vidaza® (5-azacitidine) in Australia

MELBOURNE, AUSTRALIA–Celgene Pty Ltd and Juno Pharmaceuticals Pty Ltd today announced the signing of a definitive agreement in which Celgene has appointed Juno as its strategic partner for its maturing brand – Vidaza® in Australia. Read more

Juno Appointed Exclusive Distributor for Hexvix®

Juno Pharmaceuticals is excited to announced it has been appointed as the exclusive distributor in Australia and New Zealand for Hexvix® (hexaminolevulinate hydro-chloride), an innovative breakthrough technology to aid in the diagnosis and management of non-muscle-invasive bladder cancer. The registration process will begin immediately with hopes that this product will be registered in 2016. Read more

Medical Device Approval

Juno Pharmaceuticals is pleased to announce the TGA granted approval for the following Medical Device Class 3 application in February 2015: Read more